Acasti announces completion of patient enrollment in pivotal phase 3 strive-on safety trial of gtx-104

Data readout expected early calendar 2025; nda submission on track for 1h calendar 2025 data readout expected early calendar 2025; nda submission on track for 1h calendar 2025

ACST Ratings Summary

ACST Quant Ranking